Literature DB >> 23094294

[Clinical usage of Yi-gan san-schizophrenia, borderline personality disorder, dyskinesia etc-].

Jyun Horiguchi1.   

Abstract

Yi-gan san (YGS, yokukan-san in Japanese) was developed in 1555 by Xue Kai as a remedy for restlessness and agitation in children. Prompted by the increasing life expectancy of the Japanese population, geriatricians have begun to use this traditional regimen for behavioral and psychological symptoms of dementia in the elderly. Moreover, we reported that YGS therapy is a well-tolerated and effective remedy that improves the symptoms of schizophrenia., borderline personality disorder, Charles Bonnet Syndrome, pervasive developmental disorder. Asperger's disorder, neuroleptics induced tardive dyskinesia, and restless legs syndrome. In a pilot investigation, we administered YGS as an open-label adjunct to antipsychotic medication to patients with treatment-resistant shizophrenia, borderline personality disorder, Charles Bonnet Syndrome, pervasive developmental disorder, Asperger's disorder, neuroleptics induced tardive dyskinesia. The present lecture summarizes the available data based on the above our data. In addition, we extend our discussion to the potential applications of YGS for combining this treatment with cellular and molecular therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094294

Source DB:  PubMed          Journal:  Seishin Shinkeigaku Zasshi        ISSN: 0033-2658


  3 in total

1.  Simultaneous Determination of the Traditional Herbal Formula Ukgansan and the In Vitro Antioxidant Activity of Ferulic Acid as an Active Compound.

Authors:  Yu Jin Kim; Soo-Jin Jeong; Chang-Seob Seo; Hye-Sun Lim; Eunjin Sohn; Jiyeon Yun; Bu-Yeo Kim
Journal:  Molecules       Date:  2018-07-07       Impact factor: 4.411

Review 2.  Yokukansan and its ingredients as possible treatment options for schizophrenia.

Authors:  Chuan-Hsun Yu; Ryouhei Ishii; Shun-Chieh Yu; Masatoshi Takeda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-01       Impact factor: 2.570

Review 3.  Disease- and treatment-associated acquired glucocorticoid resistance.

Authors:  Legh Wilkinson; Nicolette J D Verhoog; Ann Louw
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.